Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients

Detalhes bibliográficos
Autor(a) principal: Ribeirinho-Soares, S
Data de Publicação: 2021
Outros Autores: Pádua, D, Amaral, AL, Valentini, E, Azevedo, D, Marques, C, Barros, R, Macedo, F, Mesquita, P, Almeida, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/152463
Resumo: Background: Colorectal cancer (CRC) remains a serious health concern worldwide. Despite advances in diagnosis and treatment, about 15 to 30% of stage II CRC patients subjected to tumor resection with curative intent, develop disease relapse. Moreover, the therapeutic strategy adopted after surgery is not consensual for these patients. This supports the imperative need to find new prognostic and predictive biomarkers for stage II CRC. Methods: For this purpose, we used a one-hospital series of 227 stage II CRC patient samples to assess the biomarker potential of the immunohistochemical expression of MUC2 mucin and CDX2 and SOX2 transcription factors. The Kaplan-Meier method was used to generate disease-free survival curves that were compared using the log-rank test, in order to determine prognosis of cases with different expression of these proteins, different mismatch repair (MMR) status and administration or not of adjuvant chemotherapy. Results: In this stage II CRC series, none of the studied biomarkers showed prognostic value for patient outcome. However low expression of MUC2, in cases with high expression of CDX2, absence of SOX2 or MMR-proficiency, conferred a significantly worst prognosis. Moreover, cases with low expression of MUC2 showed a significantly clear benefit from treatment with adjuvant chemotherapy. Conclusion: In conclusion, we observe that patients with stage II CRC with low expression of MUC2 in the tumor respond better when treated with adjuvant chemotherapy. This observation supports that MUC2 is involved in resistance to fluorouracil-based adjuvant chemotherapy and might be a promising future predictive biomarker in stage II CRC patients.
id RCAP_694a6a343619707c9f248bad52eeb48d
oai_identifier_str oai:repositorio-aberto.up.pt:10216/152463
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patientsBiomarkersCDX2MUC2SOX2Stage II colorectal cancerBackground: Colorectal cancer (CRC) remains a serious health concern worldwide. Despite advances in diagnosis and treatment, about 15 to 30% of stage II CRC patients subjected to tumor resection with curative intent, develop disease relapse. Moreover, the therapeutic strategy adopted after surgery is not consensual for these patients. This supports the imperative need to find new prognostic and predictive biomarkers for stage II CRC. Methods: For this purpose, we used a one-hospital series of 227 stage II CRC patient samples to assess the biomarker potential of the immunohistochemical expression of MUC2 mucin and CDX2 and SOX2 transcription factors. The Kaplan-Meier method was used to generate disease-free survival curves that were compared using the log-rank test, in order to determine prognosis of cases with different expression of these proteins, different mismatch repair (MMR) status and administration or not of adjuvant chemotherapy. Results: In this stage II CRC series, none of the studied biomarkers showed prognostic value for patient outcome. However low expression of MUC2, in cases with high expression of CDX2, absence of SOX2 or MMR-proficiency, conferred a significantly worst prognosis. Moreover, cases with low expression of MUC2 showed a significantly clear benefit from treatment with adjuvant chemotherapy. Conclusion: In conclusion, we observe that patients with stage II CRC with low expression of MUC2 in the tumor respond better when treated with adjuvant chemotherapy. This observation supports that MUC2 is involved in resistance to fluorouracil-based adjuvant chemotherapy and might be a promising future predictive biomarker in stage II CRC patients.BMC20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/152463eng1471-240710.1186/s12885-021-08070-6Ribeirinho-Soares, SPádua, DAmaral, ALValentini, EAzevedo, DMarques, CBarros, RMacedo, FMesquita, PAlmeida, Rinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T16:01:48Zoai:repositorio-aberto.up.pt:10216/152463Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:36:52.395853Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
title Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
spellingShingle Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
Ribeirinho-Soares, S
Biomarkers
CDX2
MUC2
SOX2
Stage II colorectal cancer
title_short Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
title_full Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
title_fullStr Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
title_full_unstemmed Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
title_sort Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
author Ribeirinho-Soares, S
author_facet Ribeirinho-Soares, S
Pádua, D
Amaral, AL
Valentini, E
Azevedo, D
Marques, C
Barros, R
Macedo, F
Mesquita, P
Almeida, R
author_role author
author2 Pádua, D
Amaral, AL
Valentini, E
Azevedo, D
Marques, C
Barros, R
Macedo, F
Mesquita, P
Almeida, R
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ribeirinho-Soares, S
Pádua, D
Amaral, AL
Valentini, E
Azevedo, D
Marques, C
Barros, R
Macedo, F
Mesquita, P
Almeida, R
dc.subject.por.fl_str_mv Biomarkers
CDX2
MUC2
SOX2
Stage II colorectal cancer
topic Biomarkers
CDX2
MUC2
SOX2
Stage II colorectal cancer
description Background: Colorectal cancer (CRC) remains a serious health concern worldwide. Despite advances in diagnosis and treatment, about 15 to 30% of stage II CRC patients subjected to tumor resection with curative intent, develop disease relapse. Moreover, the therapeutic strategy adopted after surgery is not consensual for these patients. This supports the imperative need to find new prognostic and predictive biomarkers for stage II CRC. Methods: For this purpose, we used a one-hospital series of 227 stage II CRC patient samples to assess the biomarker potential of the immunohistochemical expression of MUC2 mucin and CDX2 and SOX2 transcription factors. The Kaplan-Meier method was used to generate disease-free survival curves that were compared using the log-rank test, in order to determine prognosis of cases with different expression of these proteins, different mismatch repair (MMR) status and administration or not of adjuvant chemotherapy. Results: In this stage II CRC series, none of the studied biomarkers showed prognostic value for patient outcome. However low expression of MUC2, in cases with high expression of CDX2, absence of SOX2 or MMR-proficiency, conferred a significantly worst prognosis. Moreover, cases with low expression of MUC2 showed a significantly clear benefit from treatment with adjuvant chemotherapy. Conclusion: In conclusion, we observe that patients with stage II CRC with low expression of MUC2 in the tumor respond better when treated with adjuvant chemotherapy. This observation supports that MUC2 is involved in resistance to fluorouracil-based adjuvant chemotherapy and might be a promising future predictive biomarker in stage II CRC patients.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/152463
url https://hdl.handle.net/10216/152463
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1471-2407
10.1186/s12885-021-08070-6
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136276392181760